Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Doran

Showing results (531-540 of 549) with videos related to

Pageof 55
Sort By:
Addiction (Abingdon, England)|December 28, 2018
The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trialDennis Thomas, Michael Farrell, Hayden McRobbie, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2010
Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the ratPaul J Coleman, John D Schreier, Anthony J Roecker, et al.
Annals of Internal Medicine|November 15, 1993
Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trialD R Snydman, B G Werner, N N Dougherty, et al.
Brain Research|September 3, 2011
TASK-3 as a potential antidepressant targetAnthony L Gotter, Vincent P Santarelli, Scott M Doran, et al.
The Journal of Clinical Investigation|May 20, 2009
Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in miceVictor N Uebele, Anthony L Gotter, Cindy E Nuss, et al.
Chemmedchem|September 15, 2011
Discovery of a pharmacologically active antagonist of the two-pore-domain potassium channel K2P9.1 (TASK-3)Craig A Coburn, Yunfu Luo, Mingxiang Cui, et al.
American Journal of Preventive Medicine|November 23, 2019
Part II: A Qualitative Study of Social Risk Screening Acceptability in Patients and CaregiversElena Byhoff, Emilia H De Marchis, Danielle Hessler, et al.
Australian and New Zealand Journal of Public Health|September 19, 2022
Most common principal diagnoses assigned to Australian emergency department presentations involving alcohol use: a multi-centre studyPeter Miller, Thea Vakidis, Nicholas Taylor, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2010
Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonistsKelly-Ann S Schlegel, Zhi-Qiang Yang, Thomas S Reger, et al.
JAMA|July 6, 2021
Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical TrialRyan J Courtney, Hayden McRobbie, Piotr Tutka, et al.
Pageof 55

Showing results (531-540 of 549) with videos related to

Sort By:
Pageof 55
Addiction (Abingdon, England)|December 28, 2018
The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trialDennis Thomas, Michael Farrell, Hayden McRobbie, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2010
Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the ratPaul J Coleman, John D Schreier, Anthony J Roecker, et al.
Annals of Internal Medicine|November 15, 1993
Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trialD R Snydman, B G Werner, N N Dougherty, et al.
Brain Research|September 3, 2011
TASK-3 as a potential antidepressant targetAnthony L Gotter, Vincent P Santarelli, Scott M Doran, et al.
The Journal of Clinical Investigation|May 20, 2009
Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in miceVictor N Uebele, Anthony L Gotter, Cindy E Nuss, et al.
Chemmedchem|September 15, 2011
Discovery of a pharmacologically active antagonist of the two-pore-domain potassium channel K2P9.1 (TASK-3)Craig A Coburn, Yunfu Luo, Mingxiang Cui, et al.
American Journal of Preventive Medicine|November 23, 2019
Part II: A Qualitative Study of Social Risk Screening Acceptability in Patients and CaregiversElena Byhoff, Emilia H De Marchis, Danielle Hessler, et al.
Australian and New Zealand Journal of Public Health|September 19, 2022
Most common principal diagnoses assigned to Australian emergency department presentations involving alcohol use: a multi-centre studyPeter Miller, Thea Vakidis, Nicholas Taylor, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2010
Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonistsKelly-Ann S Schlegel, Zhi-Qiang Yang, Thomas S Reger, et al.
JAMA|July 6, 2021
Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical TrialRyan J Courtney, Hayden McRobbie, Piotr Tutka, et al.
Pageof 55